


FORM PTO 1449 (modified)	Atty. Docket No. X-11965	Serial No 09/647,278	RECEIVED
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Janet M. Hock		
	Filing Date 9/26/2000	Group 4654 1646	



MAY 18 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub- class	Filing Date If Appropriate
RLi	AA	4,086,196	4/25/78	Tregear			
RLi	AB	4,698,328	10/6/87	Neer et al.			
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub- class	Translation	
							yes	no
RLi	BA	98/14478	09.04.98	WO				
RLi	BB	99/12561	18.03.99	WO				
RLi	BC	08073376	19.03.96	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RLi	CA	Hirano T, et al., "Anabolic Effects of Human Biosynthetic Parathyroid Hormone Fragment (1034), LY333334, on Remodeling and Mechanical Properties of Cortical Bone in Rabbits," <i>Journal of Bone and Mineral Research</i> , Vol. 14, No.4, 536-545 (1999).
	CB	Lindsay, R. et al., "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis," <i>The Lancet</i> , Vol. 350, 550-555 (1997).
	CC	Macgill, K. et al., "Vascular Effects of PTHrP (1-34) and PTH (1-34) in the Human Fetal-Placental Circulation," <i>Placenta</i> , Vol. 18, 587-592 (1997).
	CD	Lindsay, R. et al., "Subcutaneous Administration of the Amino-Terminal Fragment of Human Parathyroid Hormone- (1-34): Kinetics and Biochemical Response in Estrogenized Osteoporotic Patients," <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 77, No. 6, 1535-1539 (1993).
	CE	Lane, N. et al., "Parathyroid Hormone Treatment Can Reverse Corticosteroid-Induced Osteoporosis," <i>J. Clin. Invest.</i> , Vol. 102, No. 8, 1627-1633 (October 1998).
	CF	Cosman F. et al., "Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence," <i>Calcified Tissue International</i> , Vol. 62, 475-480 (1998).
	CG	Hesch, R.D. et al., "Results of a Stimulatory Therapy of Low Bone Metabolism in Osteoporosis with (1-38)hPTH and Diphosphonate EHDP," <i>Klinische Wochen Schrift</i> , Vol. 66, 976-984 (1988).
	CH	Cosman, F., et al., "Estrogen Protection against Bone Resorbing Effects of Parathyroid Hormone Infusion," <i>Annals of Internal Medicine</i> , Vol. 118, No. 5, 337-343 (1993).

EXAMINER

Ruiming L.

DATE CONSIDERED

7/29/2002


*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



FORM PTO 1449		Atty. Docket No. X-11965	Serial No 09/647,278
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Janet M. Hock	
		Filing Date 9/26/2000	Group 1654 1646
RLi	CI	Ejersted, C. et al., "Human Parathyroid Hormone (1034) and (1084) Increase the Mechanical Strength and Thickness of Cortical Bone in Rats," "Journal of Bone and Mineral Research, Vol. 3, No. 9, 1097-1101 (1993).	
	CJ	Jerome, C.P. et al., "Effect of Treatment For 3 Months With Human Parathyroid Hormone 1-34 Peptide in Ovariectomized Cynomolgus Monkeys (Macaca fascicularis)," Bone, Vol. 17, No.4, Supplement, 415S-420S (1995).	
	CK	Dempster D.W., et al., "Anabolic Actions of Parathyroid Hormone on Bone," Endocrine Reviews, Vol. 14, No. 6, 690-709, (1993).	
	CL	Fujita, T., et al., "Effect of an Intermittent Weekly Dose of Human Parathyroid Hormone (1-34) on Osteoporosis: A Randomized Double-Masked Prospective Study Using Three Dose Levels," Osteoporosis International, Vol. 9, 296-306 (1999).	
	CM	Hesch, R.D. et al., "Increase of Vertebral Density by Combination Therapy with Pulsatile 1-38hPTH and Sequential Addition of Calcitonin Nasal Spray in Osteoporotic Patients," Calcified Tissue International, Vol. 44, 176-180, (1989).	
	CN	Hodsman, A.B. et al., "A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis," Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 2, 620-628, (1997).	
	CO	Reeve, J. et al., "Anabolic Effect of Human Parathyroid Hormone Fragment on Trabecular Bone in Involutional Osteoporosis: A Multicentre Trial," British Medical Journal, Vol. 280, 1340-1344, (1980).	
	CP	Hesp, R. et al., "The Relationship between Changes in Femoral Bone Density and Calcium Balance in Patients with Involutional Osteoporosis Treated with Human Parathyroid Hormone Fragment (hPTH 1034)," Metabolic Bone Disease & Related Research, Vol. 2, 331-334, (1981).	
	CQ	Reeve, J. et al., "hPTH 1-34 Treatment of Osteoporosis with Added Hormone Replacement Therapy: Biochemical, Kinetic and Histological Responses," Osteoporosis International, Vol. 1, 162-170, (1991).	
	CR	Reeve, J. et al., "Human Parathyroid Peptide Treatment of Vertebral Osteoporosis," Osteoporosis International, Vol. 1 Supplement, S199-203, (1993).	
	CS	Slovik, D. M. et al., "Restoration of Spinal Bone in Osteoporotic Men by Treatment With Human Parathyroid Hormone (1-34) and 1,25-Dihydroxyvitamin D," Journal of Bone and Mineral Research, Vol. 1, No. 4, 377-381, (1986).	
	CT	Neer, R.M. et al., "The Use of Parathyroid Hormone Plus 1, 25-dihydroxyvitamin D to Increase Trabecular Bone in Osteoporotic Men and Postmenopausal Women," Osteoporosis, Vol. 2, 829-835, (1987).	
	CU	Reeve, J. et al., "Periodic Courses of Human 1-34 Parathyroid Peptide Alternating With Calcitriol Paradoxically Reduce Bone Remodelling in Spinal Osteoporosis," European journal of Clinical Investigation, Vol. 17, 421-428, (1987).	
	CV	Reeve, J. et al., "Treatment of Osteoporosis with Human Parathyroid Peptide and Observations on Effect of Sodium Fluoride," BMJ, Vol. 301, 134-318 (1990).	
	CW	Dempster, D.W. et al., "Anabolic Actions of Parathyroid Hormone on Bone," Endocrine Reviews, Vol. 14, No.6, 690-709, (1993).	
	CX	Riggs, B.L. et al., "Formation-Stimulating Regimens Other Than Sodium Fluoride," The American Journal of Medicine, Vol. 95 supplement 5A, 5A-62S - 5A-68S (1993).	
EXAMINER		DATE CONSIDERED	
RuiXiang Li		7/29/2002	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

FORM PTO 1449 (modified)			Atty. Docket No. X-11965	Serial No 09/647,278
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Janet M. Hock	
			Filing Date 9/26/2000	Group 1654 1646
RL	CY		Neer, D.M. et al., "Treatment of Postmenopausal Osteoporosis with Daily Parathyroid Hormone Plus Calcitriol," <i>Osteoporosis International</i> , Vol. 1 Supplement, S204-205, (1993).	
	CZ		Whitfield, J.F. et al., "Small Bone-Building Fragments of Parathyroid Hormone: New Therapeutic Agents for Osteoporosis," <i>TIPS</i> , Vol. 16, 382-386, (1995).	
	CAA		Sone, T. et al., "A Small Dose of Human Parathyroid Hormone (1034) Increased Bone Mass in the Lumbar Vertebrae in Patients with Senile Osteoporosis," <i>Miner Electrolyte Metab</i> , Vol. 21, 232-235 (1995).	
	CAB		Reginster, J.Y. et al., "Parathyroid Hormone in the Treatment of Involutional Osteoporosis: Back to the Future," <i>Osteoporosis International</i> , Vol. 7 Supplement 3, S163-S168 (1997).	
	CAC		Smith, S.Y. et al., "Efficacy of Recombinant Human Parathyroid Hormone (1-84) (rhPTH, (1-84)) in Ovariectomized Rhesus Monkeys," <i>Journal of Bone and Mineral Research</i> , Vol. 23, No.5, SA456 Abstract, S633, (1998).	
	CAD		Finkelstein, J.S. et al., "Increases in bone density after discontinuation of long-term GnRH analog and PTH administration in women with endometriosis," <i>Journal of Bone and Mineral Research</i> , Vol. 23, Supplement No. 5, F459 Abstract, S518, (1998).	
	CAE		Finkelstein, J.S. et al., "Increases in Bone Mineral Density after Discontinuation of Daily Human Parathyroid Hormone and Gonadotropin-Releasing Hormone Analog Administration in Women with Endometriosis," <i>The Journal of Clinical Endocrinology & Metabolism</i> , Vol. 84, No.4, 1214-1219 (1999).	
	CAF		Reeve, J. et al., "The Therapeutic Use of Human Parathyroid Hormone Fragment (hPTH 1-34) in Osteoporosis: Optimizing the Anabolic Effect on Trabecular and Cortical Bone," <i>Monoclonal Antibodies and Developments in Immunoassay</i> , Proceedings of the 3 rd International Conference on Radioimmunoassay 1981 held in Gardone Riviera, Italy, May 6-9, 1981. 239-246.	
	CAG		Finkelstein, J.S. et al., "Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone-(1-34)," <i>JAMA</i> , Vol. 280, No. 12, 1067-1073 (1998).	
	CAH		Finkelstein, J.S. et al., "Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency," <i>The New England Journal of Medicine</i> , Vol. 331, No. 24, 1618-1623, (1994).	
	CAI		Hodsman, A.B. et al., "Parathyroid Hormone: The Clinical Experience and Prospects," Chapter 4, 83-108 (1998).	
	CAJ		Rittmaster, R.S. et al., "Treatment of Osteoporosis with Parathyroid Hormone Followed by Alendronate. Bone Marker Results," <i>Bone</i> , Vol. 23, (Suppl.), No.5, S516-S517, Abstract F451, (1998).	
duplicate of CB	CAK		Lindsay, R. et al., "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis," <i>The Lancet</i> , Vol. 350, 550-555 (1997).	
	CAL			
	CAM			
	CAN			
	CAO			
	CAP			
EXAMINER Ruixiang L.			DATE CONSIDERED 7/29/2002	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				

FORM PTO 1449 (modified)	Atty. Docket No. X-11965	Serial No 09/647,278	RECEIVED MAY 18 2001 TECH CENTER 1600/290
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Janet M. Hock		
	Filing Date 9/26/2000	Group 1654 1646	



U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date if Appropriate
RLi	AA	4,086,196	4/25/78	Tregear			
RLi	AB	4,698,328	10/6/87	Neer et al.			
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation	
							yes	no
RLi	BA	98/14478	09.04.98	WO				
RLi	BB	99/12561	18.03.99	WO				
RLi	BC	08073376	19.03.96	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RLi	CA		Hirano T, et al., "Anabolic Effects of Human Biosynthetic Parathyroid Hormone Fragment (1034), LY333334, on Remodeling and Mechanical Properties of Cortical Bone in Rabbits," <i>Journal of Bone and Mineral Research</i> , Vol. 14, No.4, 536-545 (1999).					
	CB		Lindsay, R. et al., "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis," <i>The Lancet</i> , Vol. 350, 550-555 (1997).					
	CC		Macgill, K. et al., "Vascular Effects of PTHrP (1-34) and PTH (1-34) in the Human Fetal-Placental Circulation," <i>Placenta</i> , Vol. 18, 587-592 (1997).					
	CD		Lindsay, R. et al., "Subcutaneous Administration of the Amino-Terminal Fragment of Human Parathyroid Hormone- (1-34): Kinetics and Biochemical Response in Estrogenized Osteoporotic Patients," <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 77, No. 6, 1535-1539 (1993).					
	CE		Lane, N. et al., "Parathyroid Hormone Treatment Can Reverse Corticosteroid-Induced Osteoporosis," <i>J. Clin. Invest.</i> , Vol. 102, No. 8, 1627-1633 (October 1998).					
	CF		Cosman F. et al., "Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence," <i>Calcified Tissue International</i> , Vol. 62, 475-480 (1998).					
	CG		Hesch, R.D. et al., "Results of a Stimulatory Therapy of Low Bone Metabolism in Osteoporosis with (1-38)hPTH and Diphosphonate EHDP," <i>Klinische Wochen Schrift</i> , Vol. 66, 976-984 (1988).					
↓	CH		Cosman, F., et al., "Estrogen Protection against Bone Resorbing Effects of Parathyroid Hormone Infusion," <i>Annals of Internal Medicine</i> , Vol. 118, No. 5, 337-343 (1993).					

EXAMINER

Ruixiang L.


DATE CONSIDERED

7/29/2002

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



FORM PTO 1449		Modified	Atty. Docket No. X-11965	Serial No 09/647,278
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Janet M. Hock	
			Filing Date 9/26/2000	Group 1654 1646
RLi	CI		Ejersted, C. et al., "Human Parathyroid Hormone (1034) and (1084) Increase the Mechanical Strength and Thickness of Cortical Bone in Rats," <i>Journal of Bone and Mineral Research</i> , Vol. 3, No. 9, 1097-1101 (1993).	
	CJ		Jerome, C.P. et al., "Effect of Treatment For 3 Months With Human Parathyroid Hormone 1-34 Peptide in Ovariectomized Cynomolgus Monkeys (Macaca fascicularis)," <i>Bone</i> , Vol. 17, No.4, Supplement, 415S-420S (1995).	
	CK		Dempster D.W., et al., "Anabolic Actions of Parathyroid Hormone on Bone," <i>Endocrine Reviews</i> , Vol. 14, No. 6, 690-709, (1993).	
	CL		Fujita, T., et al., "Effect of an Intermittent Weekly Dose of Human Parathyroid Hormone (1-34) on Osteoporosis: A Randomized Double-Masked Prospective Study Using Three Dose Levels," <i>Osteoporosis International</i> , Vol. 9, 296-306 (1999).	
	CM		Hesch, R.D. et al., "Increase of Vertebral Density by Combination Therapy with Pulsatile 1-38hPTH and Sequential Addition of Calcitonin Nasal Spray in Osteoporotic Patients," <i>Calcified Tissue International</i> , Vol. 44, 176-180, (1989).	
	CN		Hodsman, A.B. et al., "A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis," <i>Journal of Clinical Endocrinology and Metabolism</i> , Vol. 82, No. 2, 620-628, (1997).	
	CO		Reeve, J. et al., "Anabolic Effect of Human Parathyroid Hormone Fragment on Trabecular Bone in Involutional Osteoporosis: A Multicentre Trial," <i>British Medical Journal</i> , Vol. 280, 1340-1344, (1980).	
	CP		Hesp, R. et al., "The Relationship between Changes in Femoral Bone Density and Calcium Balance in Patients with Involutional Osteoporosis Treated with Human Parathyroid Hormone Fragment (hPTH 1034)," <i>Metabolic Bone Disease & Related Research</i> , Vol. 2, 331-334, (1981).	
	CQ		Reeve, J. et al., "hPTH 1-34 Treatment of Osteoporosis with Added Hormone Replacement Therapy: Biochemical, Kinetic and Histological Responses," <i>Osteoporosis International</i> , Vol. 1, 162-170, (1991).	
	CR		Reeve, J. et al., "Human Parathyroid Peptide Treatment of Vertebral Osteoporosis," <i>Osteoporosis International</i> , Vol. 1 Supplement, S199-203, (1993).	
	CS		Slovik, D. M. et al., "Restoration of Spinal Bone in Osteoporotic Men by Treatment With Human Parathyroid Hormone (1-34) and 1,25-Dihydroxyvitamin D," <i>Journal of Bone and Mineral Research</i> , Vol. 1, No. 4, 377-381, (1986).	
	CT		Neer, R.M. et al., "The Use of Parathyroid Hormone Plus 1, 25-dihydroxyvitamin D to Increase Trabecular Bone in Osteoporotic Men and Postmenopausal Women," <i>Osteoporosis</i> , Vol. 2, 829-835, (1987).	
	CU		Reeve, J. et al., "Periodic Courses of Human 1-34 Parathyroid Peptide Alternating With Calcitriol Paradoxically Reduce Bone Remodelling in Spinal Osteoporosis," <i>European journal of Clinical Investigation</i> , Vol. 17, 421-428, (1987).	
	CV		Reeve, J. et al., "Treatment of Osteoporosis with Human Parathyroid Peptide and Observations on Effect of Sodium Fluoride," <i>BMJ</i> , Vol. 301, 134-138 (1990).	
	CW		Dempster, D.W. et al., "Anabolic Actions of Parathyroid Hormone on Bone," <i>Endocrine Reviews</i> , Vol. 14, No.6, 690-709, (1993).	
	CX		Riggs, B.L. et al., "Formation-Stimulating Regimens Other Than Sodium Fluoride," <i>The American Journal of Medicine</i> , Vol. 95 supplement 5A, 5A-62S - 5A-68S (1993).	
EXAMINER			DATE CONSIDERED	
Ruixiang L.			7/29/2002	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				



FORM PTO 1449 (modified)		Atty. Docket No. X-11965	Serial No 09/647,278
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Janet M. Hock	
		Filing Date 9/26/2000	Group 1654 1646
RLi	CY	Neer, D.M. et al., "Treatment of Postmenopausal Osteoporosis with Daily Parathyroid Hormone Plus Calcitriol," <i>Osteoporosis International</i> , Vol. 1 Supplement, S204-205, (1993).	
	CZ	Whitfield, J.F. et al., "Small Bone-Building Fragments of Parathyroid Hormone: New Therapeutic Agents for Osteoporosis," <i>TIPS</i> , Vol. 16, 382-386, (1995).	
	CAA	Sone, T. et al., "A Small Dose of Human Parathyroid Hormone (1034) Increased Bone Mass in the Lumbar Vertebrae in Patients with Senile Osteoporosis," <i>Miner Electrolyte Metab</i> , Vol. 21, 232-235 (1995).	
	CAB	Reginster, J.Y. et al., "Parathyroid Hormone in the Treatment of Involutional Osteoporosis: Back to the Future," <i>Osteoporosis International</i> , Vol. 7 Supplement 3, S163-S168 (1997).	
	CAC	Smith, S.Y. et al., "Efficacy of Recombinant Human Parathyroid Hormone (1-84) (rhPTH, (1-84)) in Ovariectomized Rhesus Monkeys," <i>Journal of Bone and Mineral Research</i> , Vol. 23, No.5, SA456 Abstract, S633, (1998).	
	CAD	Finkelstein, J.S. et al., "Increases in bone density after discontinuation of long-term GnRH analog and PTH administration in women with endometriosis," <i>Journal of Bone and Mineral Research</i> , Vol. 23, Supplement No. 5, F459 Abstract, S518, (1998).	
	CAE	Finkelstein, J.S. et al., "Increases in Bone Mineral Density after Discontinuation of Daily Human Parathyroid Hormone and Gonadotropin-Releasing Hormone Analog Administration in Women with Endometriosis," <i>The Journal of Clinical Endocrinology & Metabolism</i> , Vol. 84, No.4, 1214-1219 (1999).	
	CAF	Reeve, J. et al., "The Therapeutic Use of Human Parathyroid Hormone Fragment (hPTH 1-34) in Osteoporosis: Optimizing the Anabolic Effect on Trabecular and Cortical Bone," <i>Monoclonal Antibodies and Developments in Immunoassay</i> , Proceedings of the 3 rd International Conference on Radioimmunoassay 1981 held in Gardone Riviera, Italy, May 6-9, 1981. 239-246.	
	CAG	Finkelstein, J.S. et al., "Prevention of Estrogen Deficiency-Related Bone Loss With Human Parathyroid Hormone-(1-34)," <i>JAMA</i> , Vol. 280, No. 12, 1067-1073 (1998).	
	CAH	Finkelstein, J.S. et al., "Parathyroid Hormone for the Prevention of Bone Loss Induced by Estrogen Deficiency," <i>The New England Journal of Medicine</i> , Vol. 331, No. 24, 1618-1623, (1994).	
	CAI	Hodsman, A.B. et al., "Parathyroid Hormone: The Clinical Experience and Prospects," Chapter 4, 83-108 (1998).	
	CAJ	Rittmaster, R.S. et al., "Treatment of Osteoporosis with Parathyroid Hormone Followed by Alendronate. Bone Marker Results," <i>Bone</i> , Vol. 23, (Suppl.), No.5, S516-S517, Abstract F451, (1998).	
	CAK	Lindsay, R. et al., "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis," <i>The Lancet</i> , Vol. 350, 550-555 (1997).	
	CAL		
	CAM		
	CAN		
	CAO		
	CAP		
EXAMINER		DATE CONSIDERED	
Ruixiang L.		7/29/2002	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

FORM PTO 1449 (modified)		Atty. Docket No. X-11965		Serial No 09/647,278				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Janet M. Hock, et al						
		Filing Date 9/26/2000		Group 1654-1646				
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Sub- class	Filing Date If Appropriate	
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Sub- class	Translation	
							yes	no
RLi	BD	08073376	19.03.96	JP				X
RLi	BE	08310965	26.11.96	JP				X
	BF							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
RLi duplicate of	CAL	CI	J. Bone and Mineral Research 8(9) (1993) 1097-1101 Human Parathyroid Hormone (1-34) and (1-84) Increase the Mechanical Strength and Thickness of Cortical Bone in Rats					
EXAMINER			DATE CONSIDERED					
Ruixiang L.			7/29/2002					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								



RECEIVED
MAR 14 2002
TECH CENTER 1600/2900